Therapeutics: RAD52 homolog (RAD52); breast cancer 1 early onset (BRCA1); BRCA2

Cancer

INDICATION: Cancer; leukemia

In vitro studies identified 6-hydroxy-DL-dopa as an allosteric inhibitor of RAD52 that could

Read the full 152 word article

How to gain access

Continue reading with a
two-week free trial.